Skip to content
Peptigraph home

Peptides for Diabetes

The peptides people most often research for diabetes, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
5
With human trials
5
FDA approved (any use)
3
Showing 5 peptides · ordered by search interest for this goal
  1. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38785209Human1986Animal139Summarised5FDA approved (Ozempic, Wegovy, Rybelsus)For diabetesOverview
  2. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444Human843Animal48Summarised8FDA approved (Mounjaro, Zepbound)For diabetesOverview
  3. MOTS-cMitochondrial-derived peptideHuman RCT evidence, 4 of 4Aging 2022, PMID 36490309Human25Animal16Summarised5PCAC voted 7–5 for 503A (Jul 2026)For diabetesOverview
  4. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Lancet 2026, PMID 42810372Human53Animal6Summarised5Investigational · phase 3For diabetesOverview
  5. HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4The Journal of clinical endocrinology and metabolism 2003, PMID 12679422Human923Animal80Summarised1FDA approved (prescription only)Overview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

What diabetes is

MedlinePlus says diabetes means blood glucose is too high because the body cannot make insulin, cannot use it well, or both.[6]

It explains that insulin is a hormone from the pancreas that moves glucose from the bloodstream into cells for energy.[6]

Incretin drugs lead; MOTS-c and growth hormone are different stories

Semaglutide has 1,986 human-only papers and 250 randomised trials on diabetes-related outcomes and tirzepatide 843 and 96, versus MOTS-c with 25 human-only and 16 animal papers.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); semaglutide human only 1986, animal only 139, rct 250; tirzepatide human only 843, animal only 48, rct 96; mots-c human only 25, animal only 16, rct 3; retatrutide human only 53, animal only 6, rct 6; hgh human only 923, animal only 80, rct 160. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

In a randomised trial in type 2 diabetes, mean HbA1c decreased by 1.87%, 1.89% and 2.07% with tirzepatide 5, 10 and 15 mg, versus +0.04% with placebo.[7]

In a randomised trial of orforglipron, the HbA1c change at week 40 was -1.24, -1.47 and -1.48 percentage points at 3, 12 and 36 mg, versus -0.41 with placebo.[8]

In a CagriSema trial, 73.5% of the cagrilintide-semaglutide group reached an HbA1c of 6.5% or less, versus 15.9% on placebo.[9]

In a trial of people with type 2 diabetes, the primary cardiovascular outcome occurred in 6.6% of the semaglutide group and 8.9% of the placebo group.[10]

In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity.[11]

In a randomised trial, growth hormone therapy impaired insulin-stimulated glucose uptake, by 52% at 1 wk and 39% at 6 months.[5]

What FDA labels say about approved diabetes peptides

The Ozempic label says it is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.[12]

The Mounjaro label extends the glycaemic-control indication to pediatric patients 10 years of age and older.[13]

Common questions

What are the best peptides for diabetes?

The approved ones with randomised glycaemic data are tirzepatide and semaglutide; research peptides like MOTS-c only have mouse results.[7]

Which peptides help insulin resistance?

MOTS-c prevented insulin resistance in mice, while the human trials in the files are for incretin drugs in diabetes.[11]

Is there a best peptide for insulin resistance?

In a randomised trial, GH therapy impaired insulin-stimulated glucose uptake (-52% at 1 wk). No trial cited ranks peptides for insulin resistance.[5]

Which peptides are FDA approved for diabetes?

Ozempic and Mounjaro carry type 2 diabetes indications on their labels.[12]

Sources

  1. 1Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
  2. 2Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  3. 3Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  4. 4Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  5. 5Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.The Journal of clinical endocrinology and metabolism · 2003PMID 12679422Accessed 2 Oct 2026
  6. 6Official web pageOfficial web page · web page
  7. 7Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2021PMID 34186022Accessed 2 Oct 2026
  8. 8Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
  9. 9Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  10. 10Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.The New England journal of medicine · 2016PMID 27633186Accessed 2 Oct 2026
  11. 11The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.Cell metabolism · 2015PMID 25738459Accessed 2 Oct 2026
  12. 12OZEMPIC prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  13. 13MOUNJARO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.